PwC Legal advises on exit of AI software developer Dedicaid to Telix Pharmaceuticals
PwC Legal Austria advised the founder of Dedicaid GmbH, a spin-off of the Medical University Vienna on the sale of their shares to a wholly owned subsidiary of Telix Pharmaceuticals Limited.
Dedicaid GmbH was founded in 2018 as a spin-off of the Medical University of Vienna. Its core asset is an artificial intelligence (AI) powered clinical decision support software (AI Platform) that builds on molecular imaging parameters and that can be scaled across clinical indications and imaging contrast agents.
Telix Pharmaceuticals Limited, a company listed on the Australian Securities Exchange (ASX), headquartered in Melbourne, Australia, focuses on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals. The acquisition of Dedicaid provides Telix with an AI development platform which will give Telix the ability to rapidly generate new applications from clinical imaging data. These applications have the potential to further assist clinicians in predicting disease progression and treatment response.
PwC Legal Austria, led by Christian Oehner (Managing Partner, Corporate/M&A), advised on the structuring, negotiation and the entire execution of the transaction. Vesna Radukic (Associate, Corporate/M&A), the tax experts of PwC Austria Georg Erdélyi (Partner), Martin Knobloch (Director) and Alexander Beisser (Senior Manager) as well as the Australian legal experts Aidan Douglas (Partner) and Joseph Haddad (Director, both PwC Australia) were part of the multidisciplinary and international team.
“As part of the global PwC network, we managed together with our Austrian tax experts and Australian legal experts to promptly set up a team tailored to our clients’ needs, and thus to provide our clients with holistic advice on this exciting transaction.”, comments Christian Oehner and congratulates everyone involved.
